Cargando…
Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19?
Autores principales: | Liu, Xiao, Long, Chuyan, Xiong, Qinmei, Chen, Chen, Ma, Jianyong, Su, Yuhao, Hong, Kui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803360/ https://www.ncbi.nlm.nih.gov/pubmed/33180964 http://dx.doi.org/10.1002/clc.23473 |
Ejemplares similares
-
Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
por: Liu, Xiao, et al.
Publicado: (2020) -
Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Rossato, Marco, et al.
Publicado: (2020) -
Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
por: Gupta, Nitesh, et al.
Publicado: (2020) -
To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021) -
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)